Lori Raetzman, PhD, discusses mentoring and conducting science in challenging times. When she’s not in her lab studying the effects of environmental chemicals on female reproductive aging, Lori T. Raetzman, PhD, is busy guiding the next generation of endocrine scientists, which makes her an ideal candidate to receive the Endocrine Society’s 2025 Sydney Ingber Award...
The Endocrine Society has selected Yoshitomo Hoshino, MD, PhD, as the recipient of its 2025 C. Wayne Bardin, MD, International Travel Award for his outstanding ENDO abstract and research contributions to the care of patients with bone health disorders. The C. Wayne Bardin, MD, International Travel Award was created in honor of Past President Wayne...
The Endocrine Society has appointed Manuel Tena-Sempere, MD, PhD, of the University of Cordoba in Spain, as the next editor-in-chief of its flagship basic science journal, Endocrinology, starting January 2026. Manuel Tena-Sempere is a professor of physiology at the University of Cordoba, a research group leader at the biomedical research institute of Cordoba (IMIBIC) and...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Grants Isturisa® (Osilodrostat) Expanded Indication for the Treatment of Enodogenous Hypercortisolemia in Patients with Cushing’s Syndrome On April 15, Recordati announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ISTURISA® (osilodrostat) for...
Recipient of the Endocrine Society’s 2025 Roy O. Greep Award for Outstanding Research, Barbara Kahn, MD, discovered very early on that pursuing basic science could be just as rewarding as treating patients with chronic illnesses. She tells Endocrine News about her career journey, why she relishes working with so many enthusiastic junior scientists, and the...
Last month Corcept Therapuetics Incoporated announced that the U.S. Food and Drug Administration (FDA) filed its New Drug Application (NDA) submission for the company’s proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing’s syndrome). Corcept’s NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT...
A recent study entitled “Association Between Per- and Polyfluoroalkyl Substance Exposures and Thyroid Homeostasis Parameters,” published in the Journal of Clinical Endocrinology & Metabolism, has found that exposure to per- and polyfluoroalkyl substances (PFAS) — a group of synthetic chemicals used in industrial and consumer products — may alter thyroid hormone sensitivity, potentially affecting metabolism...
Just when you thought it was time to roll up the red carpet, four Endocrine Society members have recently been announced as taking home their fair share of prestigious awards that recognize outstanding leaders in research and science. First off, the 2025 Breakthrough Prize for Life Science has been presented to Daniel J. Drucker, MD,...
Recipient of the Endocrine Society’s 2025 Roy O. Greep Award for Outstanding Research, Barbara Kahn, MD, discovered very early on that pursuing basic science could be just as rewarding as treating patients with chronic illnesses. She tells Endocrine News about her career journey, why she relishes working with so many enthusiastic junior scientists, and the...
